Latest Cardionet (BEAT) Headlines
BioTelemetry (BEAT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:33AM CDT
BioTelemetry belongs to the Medical Services industry, will be a decent pick, as the company witnessed solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
CardioNet Up 19.2% Since SmarTrend Uptrend Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 10, 11:11AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 1 month, CardioNet has returned 19.21% as of today's recent price of $10.51.
CardioNet Earnings Review: 12 Days after Announcement Shares Up 10.7% (BEAT)
Comtex SmarTrend(R) - Mon Mar 10, 7:53AM CDT
A week ago on February 26th, 2014 CardioNet (NASDAQ:BEAT) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $32.3 million. The company actually reported EPS of $0.05 on sales of $33.1 million, beating EPS estimates by $0.07 and beating revenue estimates by $0.8 million. Since the company's report, shares of CardioNet have risen from $9.85 to $10.90, representing a gain of 10.7% in the past 12 days.
Why BioTelemetry (BEAT) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:00AM CST
BioTelemetry has decent short-term momentum and solid activity on the earnings estimate revision front
25.4% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 03, 9:49AM CST
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 4 weeks, CardioNet has returned 25.40% as of today's recent price of $11.06.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Why BioTelemetry (BEAT) Is Spiking Today
at The Street - Thu Feb 27, 12:52PM CST
BioTelemetry (BEAT) rises after the company, which provides products and services to healthcare professionals to help diagnose and monitor patients, reported fourth-quarter earnings that surpassed analysts' expectations. BioTelemetry reported fourth...
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
BioTelemetry, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year-ended December 31, 2013.
CardioNet Shares Up 14.7% Since SmarTrend's Buy Recommendation (BEAT)
Comtex SmarTrend(R) - Mon Feb 24, 9:34AM CST
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 3 weeks, CardioNet has returned 14.74% as of today's recent price of $10.12.
Omnicare Earnings Rise but Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 11:30AM CST
For full year 2013, OCR's adjusted net earnings per share grew 9.9% to $3.43 from $3.12 a year ago, also lagging the Zacks Consensus Estimate of $3.61.
BioTelemetry (BEAT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:51AM CST
BioTelemetry (BEAT) Shares March Higher, Can It Continue?
Why Quintiles Transnational (Q) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:30AM CST
Quintiles Transnational has seen its Zacks Rank move up from Buy to Strong Buy over the past four weeks
Healthways Sees 4Q Loss on Lower Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:07PM CST
Healthways failed to meet its own revenue expectations of 171 to $181 million for the fourth quarter and $665-$675 million for the full year
BioTelemetry, Inc. to Release Fourth Quarter 2013 Earnings Results on February 26, 2014
GlobeNewswire - Thu Feb 13, 6:26PM CST
BioTelemetry, Inc. (Nasdaq:BEAT) will release its fourth quarter 2013 earnings on Wednesday, February 26, 2014 at 4:00 PM Eastern Time.
BioTelemetry (BEAT) Soars: Stock Up 22.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 8:39AM CST
BioTelemetry, Inc. was a big mover last session, as its shares surged over 22% on the day.
Why BioTelemetry, Globalstar, and ArthroCare Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 03, 4:15PM CST
It certainly wouldn't qualify as a bloodbath, but make no mistake about it -- it was the worst day the broad-based S&P 500 has seen in quite some time. The primary culprit that caused the markets to dive precipitously throughout the day was...
BioTelemetry prevails in court, acquires rival
AP - Mon Feb 03, 3:17PM CST
MALVERN, Pa. (AP) — Shares of wireless medical device maker BioTelemetry jumped Monday after the company announced it had prevailed in court — and subsequently acquired — a rival wireless technology company.
Why BioTelemetry (BEAT) Is Soaring Today
at The Street - Mon Feb 03, 12:47PM CST
BioTelemetry (BEAT) soars after the wireless medical technology company announces it won a patent infringement case against Mednet Healthcare Technologies. Mednet entered into a consent judgment to state that it and its subsidiaries, Heart-Care...
BioTelemetry, Inc. Announces Significant Patent Litigation Victory and the Acquisition of Mednet Healthcare Technologies, Inc.
GlobeNewswire - Mon Feb 03, 7:00AM CST
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a significant victory in the patent infringement case against Mednet Healthcare Technologies, Inc. and its subsidiaries, Heart-Care Corporation of America, Universal Medical Inc., and Universal Medical Laboratory, Inc. ("Mednet"), as well as other named defendants. Mednet entered into a consent judgment, declaring that the Mednet entities infringed on five patents owned by BioTelemetry and its subsidiary, Braemar Manufacturing, and that all five patents are valid.
BioTelemetry (BEAT): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:33AM CDT
BioTelemetry belongs to the Medical Services industry, will be a decent pick, as the company witnessed solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
CardioNet Up 19.2% Since SmarTrend Uptrend Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 10, 11:11AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 1 month, CardioNet has returned 19.21% as of today's recent price of $10.51.
CardioNet Earnings Review: 12 Days after Announcement Shares Up 10.7% (BEAT)
Comtex SmarTrend(R) - Mon Mar 10, 7:53AM CDT
A week ago on February 26th, 2014 CardioNet (NASDAQ:BEAT) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $32.3 million. The company actually reported EPS of $0.05 on sales of $33.1 million, beating EPS estimates by $0.07 and beating revenue estimates by $0.8 million. Since the company's report, shares of CardioNet have risen from $9.85 to $10.90, representing a gain of 10.7% in the past 12 days.
Why BioTelemetry (BEAT) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:00AM CST
BioTelemetry has decent short-term momentum and solid activity on the earnings estimate revision front
25.4% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 03, 9:49AM CST
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 4 weeks, CardioNet has returned 25.40% as of today's recent price of $11.06.
BioTelemetry, Inc. (BEAT) Surges: Stock Moves 13.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:21AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise by roughly 14% on the day.
Why BioTelemetry (BEAT) Is Spiking Today
at The Street - Thu Feb 27, 12:52PM CST
BioTelemetry (BEAT) rises after the company, which provides products and services to healthcare professionals to help diagnose and monitor patients, reported fourth-quarter earnings that surpassed analysts' expectations. BioTelemetry reported fourth...
Surging Rank, Surging Stock: Why BioTelemetry (BEAT) Is a Winner? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:38AM CST
BioTelemetry (BEAT) sees rank surges as well as price appreciation over the past few weeks, gaining over 36% in the past month.
BioTelemetry, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year-ended December 31, 2013.
CardioNet Shares Up 14.7% Since SmarTrend's Buy Recommendation (BEAT)
Comtex SmarTrend(R) - Mon Feb 24, 9:34AM CST
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 3 weeks, CardioNet has returned 14.74% as of today's recent price of $10.12.
Omnicare Earnings Rise but Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 11:30AM CST
For full year 2013, OCR's adjusted net earnings per share grew 9.9% to $3.43 from $3.12 a year ago, also lagging the Zacks Consensus Estimate of $3.61.
BioTelemetry (BEAT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:51AM CST
BioTelemetry (BEAT) Shares March Higher, Can It Continue?
Why Quintiles Transnational (Q) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:30AM CST
Quintiles Transnational has seen its Zacks Rank move up from Buy to Strong Buy over the past four weeks
Healthways Sees 4Q Loss on Lower Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:07PM CST
Healthways failed to meet its own revenue expectations of 171 to $181 million for the fourth quarter and $665-$675 million for the full year
BioTelemetry, Inc. to Release Fourth Quarter 2013 Earnings Results on February 26, 2014
GlobeNewswire - Thu Feb 13, 6:26PM CST
BioTelemetry, Inc. (Nasdaq:BEAT) will release its fourth quarter 2013 earnings on Wednesday, February 26, 2014 at 4:00 PM Eastern Time.
BioTelemetry (BEAT) Soars: Stock Up 22.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 8:39AM CST
BioTelemetry, Inc. was a big mover last session, as its shares surged over 22% on the day.
Why BioTelemetry, Globalstar, and ArthroCare Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 03, 4:15PM CST
It certainly wouldn't qualify as a bloodbath, but make no mistake about it -- it was the worst day the broad-based S&P 500 has seen in quite some time. The primary culprit that caused the markets to dive precipitously throughout the day was...
BioTelemetry prevails in court, acquires rival
AP - Mon Feb 03, 3:17PM CST
MALVERN, Pa. (AP) — Shares of wireless medical device maker BioTelemetry jumped Monday after the company announced it had prevailed in court — and subsequently acquired — a rival wireless technology company.
Why BioTelemetry (BEAT) Is Soaring Today
at The Street - Mon Feb 03, 12:47PM CST
BioTelemetry (BEAT) soars after the wireless medical technology company announces it won a patent infringement case against Mednet Healthcare Technologies. Mednet entered into a consent judgment to state that it and its subsidiaries, Heart-Care...
BioTelemetry, Inc. Announces Significant Patent Litigation Victory and the Acquisition of Mednet Healthcare Technologies, Inc.
GlobeNewswire - Mon Feb 03, 7:00AM CST
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a significant victory in the patent infringement case against Mednet Healthcare Technologies, Inc. and its subsidiaries, Heart-Care Corporation of America, Universal Medical Inc., and Universal Medical Laboratory, Inc. ("Mednet"), as well as other named defendants. Mednet entered into a consent judgment, declaring that the Mednet entities infringed on five patents owned by BioTelemetry and its subsidiary, Braemar Manufacturing, and that all five patents are valid.
